Intracellular localization of polymyxins in human alveolar epithelial cells.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 24 05 2018
accepted: 06 09 2018
pubmed: 26 10 2018
medline: 16 1 2020
entrez: 26 10 2018
Statut: ppublish

Résumé

Current inhaled polymyxin therapy is empirical and often large doses are administered, which can lead to pulmonary adverse effects. There is a dearth of information on the mechanisms of polymyxin-induced lung toxicity and their intracellular localization in lung epithelial cells. To investigate the intracellular localization of polymyxins in human lung epithelial A549 cells. A549 cells were treated with polymyxin B and intracellular organelles (early and late endosomes, endoplasmic reticulum, mitochondria, lysosomes and autophagosomes), ubiquitin protein and polymyxin B were visualized using immunostaining and confocal microscopy. Fluorescence intensities of the organelles and polymyxin B were quantified and correlated for co-localization using ImageJ and Imaris platforms. Polymyxin B co-localized with early endosomes, lysosomes and ubiquitin at 24 h. Significantly increased lysosomal activity and the autophagic protein LC3A were observed after 0.5 and 1.0 mM polymyxin B treatment at 24 h. Polymyxin B also significantly co-localized with mitochondria (Pearson's R = 0.45) and led to the alteration of mitochondrial morphology from filamentous to fragmented form (n = 3, P < 0.001). These results are in line with the polymyxin-induced activation of the mitochondrial apoptotic pathway observed in A549 cells. Accumulation of polymyxins on mitochondria probably caused mitochondrial toxicity, resulting in increased oxidative stress and cell death. The formation of autophagosomes and lysosomes was likely a cellular response to the polymyxin-induced stress and played a defensive role by disassembling dysfunctional organelles and proteins. Our study provides new mechanistic information on polymyxin-induced lung toxicity, which is vital for optimizing inhaled polymyxins in the clinic.

Sections du résumé

Background
Current inhaled polymyxin therapy is empirical and often large doses are administered, which can lead to pulmonary adverse effects. There is a dearth of information on the mechanisms of polymyxin-induced lung toxicity and their intracellular localization in lung epithelial cells.
Objectives
To investigate the intracellular localization of polymyxins in human lung epithelial A549 cells.
Methods
A549 cells were treated with polymyxin B and intracellular organelles (early and late endosomes, endoplasmic reticulum, mitochondria, lysosomes and autophagosomes), ubiquitin protein and polymyxin B were visualized using immunostaining and confocal microscopy. Fluorescence intensities of the organelles and polymyxin B were quantified and correlated for co-localization using ImageJ and Imaris platforms.
Results
Polymyxin B co-localized with early endosomes, lysosomes and ubiquitin at 24 h. Significantly increased lysosomal activity and the autophagic protein LC3A were observed after 0.5 and 1.0 mM polymyxin B treatment at 24 h. Polymyxin B also significantly co-localized with mitochondria (Pearson's R = 0.45) and led to the alteration of mitochondrial morphology from filamentous to fragmented form (n = 3, P < 0.001). These results are in line with the polymyxin-induced activation of the mitochondrial apoptotic pathway observed in A549 cells.
Conclusions
Accumulation of polymyxins on mitochondria probably caused mitochondrial toxicity, resulting in increased oxidative stress and cell death. The formation of autophagosomes and lysosomes was likely a cellular response to the polymyxin-induced stress and played a defensive role by disassembling dysfunctional organelles and proteins. Our study provides new mechanistic information on polymyxin-induced lung toxicity, which is vital for optimizing inhaled polymyxins in the clinic.

Identifiants

pubmed: 30357331
pii: 5144003
doi: 10.1093/jac/dky409
pmc: PMC6293086
doi:

Substances chimiques

Anti-Bacterial Agents 0
Polymyxins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-57

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI132681
Pays : United States

Références

Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
Clin Infect Dis. 2013 Jun;56(12):1685-94
pubmed: 23599308
Traffic. 2000 Sep;1(9):695-701
pubmed: 11208157
Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66
pubmed: 11994745
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28416543
PLoS One. 2016 Aug 17;11(8):e0161057
pubmed: 27532263
Toxicol Sci. 2013 Jul;134(1):1-17
pubmed: 23629515
Antimicrob Agents Chemother. 2015 Dec;59(12):7489-96
pubmed: 26392495
IUBMB Life. 2013 Mar;65(3):273-81
pubmed: 23441041
Trends Microbiol. 2014 Apr;22(4):165-7
pubmed: 24698433
J Physiol. 2012 Oct 15;590(20):5167-81
pubmed: 22826129
Antimicrob Agents Chemother. 2010 Jan;54(1):346-52
pubmed: 19884381
Core Evid. 2014 Sep 19;9:99-112
pubmed: 25278817
BMC Infect Dis. 2011 Nov 15;11:317
pubmed: 22085766
J Antimicrob Chemother. 2007 Dec;60(6):1206-15
pubmed: 17878146
J Antimicrob Chemother. 2016 Feb;71(2):403-12
pubmed: 26494147
Antimicrob Agents Chemother. 2015 Apr;59(4):2189-97
pubmed: 25645826
Expert Opin Drug Deliv. 2012 Mar;9(3):333-42
pubmed: 22332963
J Cyst Fibros. 2004 Mar;3(1):23-8
pubmed: 15463883
Clin Infect Dis. 2011 Nov;53(9):879-84
pubmed: 21900484
Antimicrob Agents Chemother. 2009 Jul;53(7):2857-64
pubmed: 19380593
N Engl J Med. 2007 Nov 29;357(22):2310-1
pubmed: 18046039
FEBS J. 2011 Apr;278(6):941-54
pubmed: 21232014
BMC Cancer. 2016 Sep 29;16(1):762
pubmed: 27687594
Am J Respir Crit Care Med. 2014 Apr 15;189(8):975-82
pubmed: 24625200
Arch Biochem Biophys. 2006 May 15;449(1-2):130-42
pubmed: 16554017
Future Microbiol. 2013 Jun;8(6):711-24
pubmed: 23701329
J Hosp Infect. 2009 Nov;73(3):239-45
pubmed: 19804919
Antimicrob Agents Chemother. 2014 Jul;58(7):4075-85
pubmed: 24798292
Antimicrob Agents Chemother. 2014 May;58(5):2570-9
pubmed: 24550334
Oncotarget. 2017 Jul 11;8(28):45117-45132
pubmed: 28187461
J Antimicrob Chemother. 2015 Dec;70(12):3291-7
pubmed: 26318190
Antimicrob Agents Chemother. 2015 Apr;59(4):2136-43
pubmed: 25624331
Clin Infect Dis. 2005 Sep 1;41(5):754-7
pubmed: 16080101
Expert Opin Pharmacother. 2014 Jul;15(10):1351-70
pubmed: 24766095
Autophagy. 2013 Dec;9(12):2115-25
pubmed: 24184927
Histol Histopathol. 2010 Jan;25(1):99-112
pubmed: 19924646
Infection. 2010 Feb;38(1):47-51
pubmed: 20108161
J Cell Sci. 2006 May 15;119(Pt 10):1977-84
pubmed: 16687735
Int J Infect Dis. 2010 Nov;14(11):e1018-9
pubmed: 20947404
J Pathol. 2010 May;221(1):3-12
pubmed: 20225336
Anal Chem. 2015 Feb 3;87(3):1590-5
pubmed: 25553489
J Histochem Cytochem. 1997 Mar;45(3):383-92
pubmed: 9071320
Int J Mol Sci. 2017 May 16;18(5):
pubmed: 28509852
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559256
PLoS One. 2017 Nov 27;12(11):e0188359
pubmed: 29176775
Eur Respir J. 2015 Dec;46(6):1732-9
pubmed: 26405294
Clin Infect Dis. 2013 Aug;57(4):524-31
pubmed: 23697744
Anesthesiology. 2012 Dec;117(6):1335-47
pubmed: 23132092
Chest. 2017 Jan;151(1):e1-e3
pubmed: 28065254
Sci Rep. 2016 Sep 09;6:32985
pubmed: 27609668
Antimicrob Agents Chemother. 2013 Dec;57(12):6319-24
pubmed: 24100504
Pharmacol Res Perspect. 2016 Feb 04;4(1):e00211
pubmed: 26977301
J Cyst Fibros. 2007 Jul;6(4):284-92
pubmed: 17185047
Clin Infect Dis. 2010 Mar 15;50(6):e38-40
pubmed: 20146630
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031207

Auteurs

Maizbha U Ahmed (MU)

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Victoria, Australia.

Tony Velkov (T)

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Qi Tony Zhou (QT)

Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN, USA.

Alex J Fulcher (AJ)

Monash Micro Imaging, Monash University, Victoria, Australia.

Judy Callaghan (J)

Monash Micro Imaging, Monash University, Victoria, Australia.

Fanfan Zhou (F)

School of Pharmacy, The University of Sydney, Camperdown, NSW, Australia.

Kim Chan (K)

School of Pharmacy, The University of Sydney, Camperdown, NSW, Australia.

Mohammad A K Azad (MAK)

Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Victoria, Australia.

Jian Li (J)

Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH